[{"address1": "3611 Valley Centre Drive", "address2": "Suite 300", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "888 969 7879", "website": "https://www.travere.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.", "fullTimeEmployees": 380, "companyOfficers": [{"maxAge": 1, "name": "Dr. Eric M. Dube Ph.D.", "age": 50, "title": "President, CEO & Director", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 1399274, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Cline C.F.A.", "age": 38, "title": "Chief Financial Officer", "yearBorn": 1985, "fiscalYear": 2023, "totalPay": 709943, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth E. Reed J.D.", "age": 52, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 713634, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William E. Rote Ph.D.", "age": 60, "title": "Senior VP and Head of Research & Development", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 748025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter  Heerma", "age": 51, "title": "Chief Commercial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 742367, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra  Calvin", "age": 57, "title": "SVP, Corporate Controller & Chief Accounting Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Naomi  Eichenbaum", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Charlotte  Smith", "title": "Senior Vice President of Public Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Angela  Giannantonio", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Casey  Logan", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 3, "compensationRisk": 5, "shareHolderRightsRisk": 3, "overallRisk": 4, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.05, "open": 10.23, "dayLow": 9.435, "dayHigh": 10.355, "regularMarketPreviousClose": 10.05, "regularMarketOpen": 10.23, "regularMarketDayLow": 9.435, "regularMarketDayHigh": 10.355, "beta": 0.712, "forwardPE": -6.20625, "volume": 1121795, "regularMarketVolume": 1121795, "averageVolume": 1092498, "averageVolume10days": 898130, "averageDailyVolume10Day": 898130, "bid": 9.92, "ask": 9.96, "bidSize": 200, "askSize": 200, "marketCap": 759560640, "fiftyTwoWeekLow": 5.12, "fiftyTwoWeekHigh": 14.82, "priceToSalesTrailing12Months": 4.275746, "fiftyDayAverage": 9.0928, "twoHundredDayAverage": 7.9477, "currency": "USD", "enterpriseValue": 846569408, "profitMargins": -0.82135004, "floatShares": 56395642, "sharesOutstanding": 76491504, "sharesShort": 9295562, "sharesShortPriorMonth": 10099233, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.12149999, "heldPercentInsiders": 0.0072500003, "heldPercentInstitutions": 1.1714801, "shortRatio": 8.97, "shortPercentOfFloat": 0.1367, "bookValue": 0.198, "priceToBook": 50.151516, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -383447008, "trailingEps": -4.98, "forwardEps": -1.6, "pegRatio": -0.01, "enterpriseToRevenue": 4.766, "enterpriseToEbitda": -3.078, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TVTX", "underlyingSymbol": "TVTX", "shortName": "Travere Therapeutics, Inc.", "longName": "Travere Therapeutics, Inc.", "firstTradeDateEpochUtc": 1352385000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "2b2caaeb-856a-3467-aaca-ee42583023f1", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.93, "targetHighPrice": 20.0, "targetLowPrice": 9.0, "targetMeanPrice": 15.0, "targetMedianPrice": 15.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 13, "totalCash": 325396000, "totalCashPerShare": 4.254, "ebitda": -275060000, "totalDebt": 403225984, "quickRatio": 2.908, "currentRatio": 3.043, "totalRevenue": 177644000, "debtToEquity": 2662.085, "revenuePerShare": 2.311, "returnOnAssets": -0.30702, "returnOnEquity": -5.82605, "freeCashflow": -224347120, "operatingCashflow": -288855008, "revenueGrowth": 0.681, "grossMargins": -0.31445, "ebitdaMargins": -1.54838, "operatingMargins": -1.23902, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]